Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Biodyne Co., Ltd. (314930:KRX), powered by AI.
Biodyne Co., Ltd. is currently trading at ₩10,400. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Biodyne Co., Ltd. on Alpha Lenz.
Biodyne Co., Ltd.'s P/E ratio is 363.5.
“Biodyne Co., Ltd. trades at a P/E of 363.5 (premium valuation) with modest ROE of 2.0%.”
Ask for details →Biodyne Co., Ltd., a biotechnology company, is dedicated to pioneering advancements in the field of life sciences. Its primary function revolves around the development and commercialization of innovative therapeutic products and diagnostic solutions, aimed at addressing various medical challenges. With a strong focus on research and development, Biodyne Co., Ltd. works on the forefront of genetic and molecular research, contributing significantly to the pharmaceutical and healthcare industries. The company's extensive product portfolio encompasses novel biologics, specialized diagnostics, and personalized medicine solutions tailored to improve patient outcomes. Operating globally, Biodyne Co., Ltd. plays a crucial role in enhancing healthcare delivery through cutting-edge technology and scientific excellence. Its collaborations with academic institutions, hospitals, and industry partners underscore its commitment to driving progress in medical science. As a key player in the biotech sector, Biodyne Co., Ltd. supports a wide array of scientific research initiatives, reinforcing its position as a leader in innovation and efficiency in medical biotechnology.
“Biodyne Co., Ltd. trades at a P/E of 363.5 (premium valuation) with modest ROE of 2.0%.”
Ask for details →Biodyne Co., Ltd. (ticker: 314930) is a company listed on KRX in the Healthcare sector (Medical Instruments & Supplies). Market cap is $309.5B.
The current price is ₩10,400 with a P/E ratio of 363.49x and P/B of 7.02x.
ROE is 1.95% and operating margin is 9.28%. Annual revenue is $7.0B.